Medicare Part D and Medicare Advantage (Part C) plans typically cover Eliquis, as it appears on most drug formularies
For instance, nearly 50% of people on these medications experience nausea, whereas vomiting and diarrhoea impact approximately 25% and 30% of users
Larger, longer, and more diverse clinical studies are still needed to clarify safety, long-term outcomes, and appropriate use
Many people find the weekly routine easy to stick with
Several studies have shown that complete withdrawal of an obesity treatment dose of a GLP-1RA without other structured care leads to weight regain in most people.2 However, it remains unclear whether lifelong treatment of obesity should always consist of GLP-1RAs at full obesity dosing or whether a range of alternative strategies can enable some subset of people with obesity to maintain their weight loss after a limited duration of initial treatment, followed by tapering, discontinuing, or off-ramping these agents." This paragraph from the article, I believe, sums up nicely what this means